Figure legends
Figure 1. DEP screening and annotation enrichment analysis of
the plasma proteome profiles of pediatric LCH patients. (A) Volcano
plot of DEPs between the MS LCH and SS LCH groups. The blue points
represent downregulated proteins, while the red points represent
upregulated proteins. (B) Hierarchical clustering heatmap of the
screened DEPs. (C) KEGG annotation and enrichment analysis of DEPs
showing the signaling pathway diagram for the enriched items. (D) Gene
Ontology annotation and enrichment analysis of DEPs, including
biological process (BP), molecular function (MF), and cellular component
(CC) terms.
Figure 2. Identification of overlapping DEPs/DEGs by scRNA-seq
versus plasma proteomics. (A) T-distributed stochastic neighbor
embedding (t-SNE) plot of nine PBMC subclusters from MS RO+ LCH (n= 7)
and SS LCH (n=3) patients. (B) Venn diagram illustrating the
intersections between the two comparisons according to plasma proteomics
versus scRNA-seq. (C) The feature plot shows the clustering of common
DEGs (CSF1R , CD14 , and GSN ) based on gene
expression. The color legend shows the log10-transformed expression
levels of the genes.
Figure 3. sCSF1R levels in plasma and CSF1R expression in LCH
lesions. (A) sCSF1R levels in plasma samples from LCH patients and
healthy children determined by ELISA. (B) Scatter plots showing the
differences in sCSF1R levels among SS, MS RO-, and MS RO+ LCH patients.
(C) Representative images of immunofluorescence staining forBRAF- V600E (pink) and CSF1R (green) in LCH skin biopsies.
Original magnification: 100×; scale bar: 50 μm. Histogram of MFI
(average fluorescence intensity) among SS, MS RO-, and MS RO+ LCH.
Figure 4. Prognostic value of plasma sCSF1R levels at
diagnosis. (A) ROC curve schematic. (B) 3-year PFS in the cohort of 104
LCH patients treated with standard first-line treatment. (C) PFS in
patients with SS LCH (n= 68). (D) 3-year PFS in patients with MS LCH (n=
36). (E-F) Univariate and multivariate analyses of prognostic factors
for PFS in children with LCH.
Figure 5. Monitoring of plasma sCSF1R levels during follow-up
in LCH patients. (A) The levels of plasma sCSF1R at two time points (at
diagnosis and at week 6) in 23 patients receiving first-line therapy.
(B-G) Dynamics of the plasma sCSF1R and cfBRAF -V600E levels in
six relapsed patients treated with BRAFi therapy. The black arrows
indicate the time points at which patients stopped treatment with
darafenib; the red arrows indicate the time of recurrence. Treatment
regimens are indicated at the bottom of each graph. The limit of the
cfBRAF -V600E detection assay was determined to be 0.1%.